X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA GSK PHARMA NATCO PHARMA/
GSK PHARMA
 
P/E (TTM) x 23.5 62.2 37.8% View Chart
P/BV x 17.8 10.0 178.1% View Chart
Dividend Yield % 0.6 1.3 50.7%  

Financials

 NATCO PHARMA   GSK PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
GSK PHARMA
Mar-17
NATCO PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs8773,838 22.9%   
Low Rs4242,637 16.1%   
Sales per share (Unadj.) Rs223.4354.2 63.1%  
Earnings per share (Unadj.) Rs31.139.8 78.1%  
Cash flow per share (Unadj.) Rs40.342.9 93.9%  
Dividends per share (Unadj.) Rs5.0030.00 16.7%  
Dividend yield (eoy) %0.80.9 83.0%  
Book value per share (Unadj.) Rs219.5236.9 92.6%  
Shares outstanding (eoy) m33.0784.70 39.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.99.1 31.8%   
Avg P/E ratio x20.981.4 25.7%  
P/CF ratio (eoy) x16.175.5 21.4%  
Price / Book Value ratio x3.013.7 21.7%  
Dividend payout %16.175.4 21.3%   
Avg Mkt Cap Rs m21,504274,216 7.8%   
No. of employees `000NA4.7 0.0%   
Total wages/salary Rs m1,1284,830 23.3%   
Avg. sales/employee Rs ThNM6,387.0-  
Avg. wages/employee Rs ThNM1,028.3-  
Avg. net profit/employee Rs ThNM717.1-  
INCOME DATA
Net Sales Rs m7,38930,000 24.6%  
Other income Rs m167728 22.9%   
Total revenues Rs m7,55630,728 24.6%   
Gross profit Rs m1,7934,190 42.8%  
Depreciation Rs m304263 115.7%   
Interest Rs m3660-   
Profit before tax Rs m1,2904,655 27.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m3091,744 17.7%   
Profit after tax Rs m1,0273,368 30.5%  
Gross profit margin %24.314.0 173.8%  
Effective tax rate %23.937.5 63.9%   
Net profit margin %13.911.2 123.9%  
BALANCE SHEET DATA
Current assets Rs m3,68116,742 22.0%   
Current liabilities Rs m3,1237,202 43.4%   
Net working cap to sales %7.631.8 23.8%  
Current ratio x1.22.3 50.7%  
Inventory Days Days8952 172.7%  
Debtors Days Days5921 282.4%  
Net fixed assets Rs m7,6858,635 89.0%   
Share capital Rs m331847 39.0%   
"Free" reserves Rs m6,67019,222 34.7%   
Net worth Rs m7,25920,069 36.2%   
Long term debt Rs m95510 9,549.0%   
Total assets Rs m11,95730,038 39.8%  
Interest coverage x4.5NM-  
Debt to equity ratio x0.10 26,400.3%  
Sales to assets ratio x0.61.0 61.9%   
Return on assets %11.711.2 103.9%  
Return on equity %14.216.8 84.3%  
Return on capital %20.725.5 81.4%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,445528 652.5%   
Fx outflow Rs m7037,193 9.8%   
Net fx Rs m2,743-6,665 -41.1%   
CASH FLOW
From Operations Rs m1,4402,360 61.0%  
From Investments Rs m-1,0893,008 -36.2%  
From Financial Activity Rs m-353-5,108 6.9%  
Net Cashflow Rs m-1260 -0.6%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 50.7 2.9%  
Indian inst/Mut Fund % 7.8 10.2 76.9%  
FIIs % 16.6 23.8 69.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 15.4 168.8%  
Shareholders   25,395 102,036 24.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SANOFI INDIA  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare NATCO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Lower; Energy Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the energy sector and auto sector witnessing maximum selling pressure.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 22, 2018 12:41 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - PFIZER COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS